Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system.
Conway, Margaret J
Morgan, A J
Qualtiere, L F
Arrand, John R
AffiliationDepartment of Molecular Biology, Paterson Institute for Cancer Research, Manchester, UK.
MetadataShow full item record
AbstractOur initial results with a bovine papilloma virus (BPV) vector expression system indicated that we could produce significant amounts of Epstein-Barr virus (EBV) gp340/220 in the supernatant of a mouse fibroblast cell line. We have now extended these findings to show that the truncated version of gp340/220, where the membrane anchor sequence is deleted, is produced even after extended passage of the cells, at a level of approximately 1 mg/4 x 10(8) cells. A simple purification protocol using Sephacryl S300HR and gelatin agarose gives a product which is greater than 90% pure. This product is recognized by anti-gp340 monoclonal antibodies from five different epitope groups and induces antibody that recognizes the authentic gp340/220 and neutralizes EBV in vitro. The purified gp340/220 can be used in ELISA and stimulates the proliferation of T-cell clones specific for gp340/220. These characteristics, together with the fact that BPV-transformed lines have been utilized for the production of pharmaceuticals for use in humans, suggest that this gp340/220 is suitable as a source of antigen for vaccination to prevent EBV infection and related diseases.
CitationPurification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system. 1992, 10 (11):777-82 Vaccine
- Expression of Epstein-Barr virus membrane antigen gp340/220 in mouse fibroblasts using a bovine papillomavirus vector.
- Authors: Conway M, Morgan A, Mackett M
- Issue date: 1989 Mar
- Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
- Authors: Finerty S, Tarlton J, Mackett M, Conway M, Arrand JR, Watkins PE, Morgan AJ
- Issue date: 1992 Feb
- In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
- Authors: Ulaeto D, Wallace L, Morgan A, Morein B, Rickinson AB
- Issue date: 1988 Nov
- MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.
- Authors: Lee SP, Wallace LE, Mackett M, Arrand JR, Searle PF, Rowe M, Rickinson AB
- Issue date: 1993 May
- The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines.
- Authors: Wilson AD, Lövgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ
- Issue date: 1999 Mar 5